1. Home
  2. AES vs CYTK Comparison

AES vs CYTK Comparison

Compare AES & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The AES Corporation

AES

The AES Corporation

HOLD

Current Price

$14.68

Market Cap

9.9B

Sector

Utilities

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$76.76

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AES
CYTK
Founded
1981
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9B
10.4B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
AES
CYTK
Price
$14.68
$76.76
Analyst Decision
Hold
Strong Buy
Analyst Count
10
19
Target Price
$15.29
$89.26
AVG Volume (30 Days)
10.6M
3.1M
Earning Date
05-01-2026
05-05-2026
Dividend Yield
4.87%
N/A
EPS Growth
N/A
N/A
EPS
0.68
N/A
Revenue
$12,233,000,000.00
$13,368,000.00
Revenue This Year
$5.22
$7.37
Revenue Next Year
$4.81
$310.19
P/E Ratio
$21.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.96
$30.56
52 Week High
$17.65
$80.20

Technical Indicators

Market Signals
Indicator
AES
CYTK
Relative Strength Index (RSI) 64.29 59.30
Support Level $14.01 $59.07
Resistance Level $15.02 $79.66
Average True Range (ATR) 0.07 2.64
MACD 0.02 -0.27
Stochastic Oscillator 85.23 60.95

Price Performance

Historical Comparison
AES
CYTK

About AES The AES Corporation

AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: